CN115697365A - 药用鱼腥草的发酵浓缩提取方法 - Google Patents
药用鱼腥草的发酵浓缩提取方法 Download PDFInfo
- Publication number
- CN115697365A CN115697365A CN202080101111.5A CN202080101111A CN115697365A CN 115697365 A CN115697365 A CN 115697365A CN 202080101111 A CN202080101111 A CN 202080101111A CN 115697365 A CN115697365 A CN 115697365A
- Authority
- CN
- China
- Prior art keywords
- powder
- houttuynia cordata
- tank
- fermentation
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000000691 Houttuynia cordata Species 0.000 title claims abstract description 76
- 235000013719 Houttuynia cordata Nutrition 0.000 title claims abstract description 74
- 238000000855 fermentation Methods 0.000 title claims abstract description 46
- 230000004151 fermentation Effects 0.000 title claims abstract description 46
- 238000000605 extraction Methods 0.000 title 1
- 239000000843 powder Substances 0.000 claims abstract description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 12
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 12
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 11
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 10
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 10
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 10
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 10
- 240000000111 Saccharum officinarum Species 0.000 claims abstract description 9
- 235000007201 Saccharum officinarum Nutrition 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 8
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 238000000227 grinding Methods 0.000 claims abstract description 4
- 238000005303 weighing Methods 0.000 claims abstract description 4
- 244000052769 pathogen Species 0.000 claims description 12
- 210000000987 immune system Anatomy 0.000 claims description 10
- 241000607142 Salmonella Species 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 239000012674 herbal formulation Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000001848 dysentery Diseases 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 206010047513 Vision blurred Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 208000002173 dizziness Diseases 0.000 claims description 2
- 235000020650 eye health related herbal supplements Nutrition 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241001136175 Burkholderia pseudomallei Species 0.000 claims 1
- 201000009182 Chikungunya Diseases 0.000 claims 1
- 208000004293 Chikungunya Fever Diseases 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 235000013717 Houttuynia Nutrition 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 208000005647 Mumps Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 claims 1
- 241000607762 Shigella flexneri Species 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000010805 mumps infectious disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract description 22
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 abstract description 13
- 229920002498 Beta-glucan Polymers 0.000 abstract description 13
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 abstract description 11
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 abstract description 11
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract description 11
- 229960001285 quercetin Drugs 0.000 abstract description 11
- 235000005875 quercetin Nutrition 0.000 abstract description 11
- 239000009141 Houttuynia cordata plant extract Substances 0.000 abstract description 6
- 235000008216 herbs Nutrition 0.000 abstract description 4
- 238000003756 stirring Methods 0.000 abstract description 4
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 239000012676 herbal extract Substances 0.000 abstract description 2
- 238000005406 washing Methods 0.000 abstract description 2
- 241000411851 herbal medicine Species 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 230000004054 inflammatory process Effects 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 5
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 206010016952 Food poisoning Diseases 0.000 description 4
- 208000019331 Foodborne disease Diseases 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 4
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 241000607768 Shigella Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 235000017807 phytochemicals Nutrition 0.000 description 3
- 229930000223 plant secondary metabolite Natural products 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000004015 melioidosis Diseases 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001148494 Cibotium Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 108010025838 dectin 1 Proteins 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000020191 long-life milk Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 108091005446 macrophage receptors Proteins 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- -1 quercetin Natural products 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Abstract
发酵和提取浓缩草药以获得更多活性药物成分的方法如下:将完好、干净的鱼腥草叶放入清水中,彻底冲洗并沥干,然后放入发酵罐;称取甘蔗粉,放在在另一个罐中,加入发酵剂,即酿酒酵母、干酪乳杆菌(GenBank基因库序号:AF320255.1)、植物乳杆菌(GenBank基因库序号:AF320256.1);加入清水至1000升,充分搅拌,然后将混合物倒入第一个发酵罐中,淹没鱼腥草叶;盖紧盖子,将发酵罐暴露在阳光下1个月;再将叶子从发酵水中取出,在100摄氏度的热风烘箱中干燥,然后研磨成细粉;将细粉与发酵水按重量比1∶2的比例在烘焙罐中混合,点燃煤气灶,同时烘焙罐缓慢转动1小时,将湿粉末加热至100‑150℃;之后,将粉末在100℃的热风烘箱中干燥8‑12小时;然后将粉末与剩余的发酵水混合,按如上步骤重复操作,直到罐中的发酵水耗尽。这样就获得了具有更多槲皮素和β‑葡聚糖的浓缩鱼腥草提取物。这种浓缩的草药提取物可用作草药或食品补充剂中的活性药物成分。
Description
技术领域
本发明涉及到鱼腥草发酵浓缩提取方法和免疫学相关化学领域。
背景技术
自1965年以来,生物发酵法在国外就已为人所知并得到广泛使用。在泰国,自1976年以来,农民就开始接触到与农业相关的用于生物发酵的有效微生物(EM)的知识。全国各地的农民得以广泛应用生物发酵的知识,并将其用于发酵许多有益健康的草本植物。传统的生物发酵方法是将各种蔬菜和草药置于在同一容器的培养基中一起发酵。这种传统发酵方法使用酿酒厂的糖蜜、甘蔗汁或蜂蜜作为密封容器中的培养基。其发酵过程中产生的气泡可以通过排气口排出。发酵过程需要大约1个月,或者直到不再有气泡冒出,发酵过程就结束了。因此,农民会倒出发酵水备用。而工业系统需要获得可用于生产和具有商业价值的具有高特异性和浓度的活性药物成分(API),传统的发酵方法可能并不适用,也不能作为工业系统中的工作模式。
本专利发明人发现:在本实施例中使用的名为鱼腥草的草药,别称侧耳根、佛耳草、猪鼻孔、狗贴耳、蕺菜等,含有许多有用的植物化学物质,如槲皮素,其具有良好的抗氧化特性,并能诱导超氧化物歧化酶;所述超氧化物歧化酶在体内作为抗氧化剂,更身体更具有活性。
也有众多报道表明,鱼腥草具有许多有趣的药理作用,如抗突变、抗癌作用,以及具有促进机体运行、抗肥胖活性、保肝、抗病毒、抗菌、消除自由基、抗白血病和治疗鼻窦炎等的作用。
根据本专利发明人提出的方法,在发酵罐中对新鲜的鱼腥草叶进行生物发酵,即可获得某些活性药物成分的浓缩物。该方法使用2-10%浓度的甘蔗(粉碎成粉末)作为培养基,在25-40℃(摄氏度)的密封罐中进行。发酵罐中就会生长繁殖出微生物。这些微生物会分解鱼腥草细胞的细胞壁,使鱼腥草细胞内许多活性物质释放出来,从而不断溶解到发酵的鱼腥草水中。充足的发酵时间,如1个月,会使得发酵过程中产生的气泡或气体通过排气通道排出,直到全部消失。而发酵罐仍然会紧紧封闭,再继续发酵3-12个月。之后,从发酵罐中取出鱼腥草叶,置于100℃的热气炉中干燥8-10小时。随后研磨干燥的鱼腥草叶得到精细的粉末。
将鱼腥草发酵罐剩余的发酵水与干燥的鱼腥草细粉末以2∶1的重量比在球形搅拌机中搅拌,该搅拌机作为烘焙罐使用。先打开电机,旋转球形搅拌机。当搅拌机旋转时,点燃煤气炉来烧烤烘焙罐外部的金属板,从而将热量从罐的外部传递到内部的湿鱼腥草粉末。这样,在搅拌罐旋转过程中,搅拌罐中鱼腥草细粉的温度将在短时间内逐渐达到 100-150℃,过程持续1小时。发酵提取的鱼腥草叶的混合物将受到数次短时间的高温刺激而不燃烧,从而激发了发酵过程中产生的植物化学物质的混合物和酶的相互作用,使得发酵的鱼腥草提取物中含有的槲皮素显著增加。然后将鱼腥草粉末在100℃的热空气烘箱中干燥8-12小时。
重复上述过程,将鱼腥草发酵罐的剩余发酵水与干燥的鱼腥草细粉以2∶1的重量比在球形搅拌机中混合,直到鱼腥草粉末干燥,如此反复,直到发酵水全部消失。
相对比新鲜的鱼腥草叶,成品中槲皮素的含量可提高至少2400倍,β-葡聚糖的含量提高至少9倍。这种成品可用于制药和医疗中,如调节免疫系统、预防和治疗人和动物的多种疾病。
此外,用上述方法强化发酵鱼腥草提取物,将得到含有益生菌死细胞的成品。如上所述,酵母(酿酒酵母)也将作为发酵的鱼腥草的活性药物成分加入。该过程也会产生酵母细胞壁结构的一种成分,即称为β-葡聚糖的物质。这种β-葡聚糖具有独特分子结构,当人和动物摄取这种糖时,可以帮助从骨髓中释放更多合格的干细胞到血液中。随后,干细胞迁移到人体各处以重塑或修复受损的细胞和组织,使其恢复正常功能,这就是人体愈合系统的运行机制。
对小鼠的实验室实验发现,当将在发酵的鱼腥草中发现的乳酸杆菌的死细胞或乳酸杆菌的2个亚种的多核苷酸皮下注射到小鼠10天时,所述菌即干酪乳杆菌(GenBank基因数据库序号:AF320255.1;网页链接:http://www.nebi.nlm.nih. gov/nuccore/AF3202551)和植物乳杆菌(GenBank基因数据库序号:AF320256.1;网页链接:http:// ncbi.nlm.nih.gov/nuccore/AF3202561)能显著增强小鼠的免疫系统,使小鼠的白细胞更有效地破坏会导致人类疾病的5种病原体,所述5种病原体如下所示。
1、类鼻疽伯克霍尔德菌。这种病原体会引起类鼻疽病,存在于人类和许多哺乳动物如山羊、绵羊、猪、牛和水牛中。这种疾病发现于澳大利亚北部、东南亚、中国南部和中国台湾。尤其是泰国,每年有2000-3000例患者,平均每10万人中有4.4例。该疾病的最高发病率出现在东北地区,尤其是在雨季。该疾病是泰国的一大公共卫生问题,因为该疾病死亡率高,尤其是血液感染患者的死亡率约为60%,并且常在患有糖尿病和肾病等慢性疾病的人群中发现严重致死症状。在短期治疗和免疫受损患者的情况中,经常有复发症状,正常饮食习惯和生活方式的改变将增加这些人中类鼻疽病的严重性。小鼠免疫试验结果表明,白细胞对类鼻疽伯克霍尔德菌的杀灭率高达95.45%。
2、志贺氏菌。这种革兰氏阴性病原体会引起痢疾,其具有带血或不带血的排便。在泰国,据报道每10万人中有3.4名志贺氏菌引起的痢疾患者。小鼠免疫试验结果表明,小鼠白细胞可100%杀灭志贺氏菌。
3、金黄色葡萄球菌。这是一种皮肤和鼻腔的特有病原体,也是食物中的重要致病菌。会在许多器官中引起感染,如引起皮肤溃疡、传染性关节炎和血流感染,导致汗腺、皮脂腺、皮下脂肪的感染,是患者住院的主要原因,比其他类型的感染时间多3倍,死亡率高5倍。这种病原体可以在有或没有空气的条件下生长。人们食用了含有耐热的有毒物质的食物,会引起食物中毒。食物中不足1微克的这些有毒物质的污染就会导致恶心、呕吐、头晕、腹部绞痛和疲劳等疾病。金黄色葡萄球菌是泰国食物中毒的首要原因,患病率约为8.25%。仅在1946年使用青霉素一年后,这种病原体就对青霉素产生了抗药性。此外,目前医学界面临的一个问题是对两组或更多组药物具有耐药性的多药耐药性生物体(MDROs)。并且,还有对所有使用的药物都有耐药性的病原体(泛耐药生物),即被称为耐甲氧西林金黄色葡萄球菌(M.R.S.A.)的革兰氏阳性菌,这是全世界医学界目前面临的大问题。根据我们的小鼠服用鱼腥草提取物的实验数据,结果显示99.46%的金黄色葡萄球菌可被小鼠白细胞杀死。另外,本专利申请发明人还遇到过,使用生物发酵鱼腥草粉末治疗在医院治疗超过10年且从未痊愈的慢性皮肤感染患者,感染伤口好转,并可在2个月内痊愈。
根据本实施例,未来主流医学策略更加有效地治疗耐药性感染疾病,可能是利用鱼腥草的新方式。
4、B群沙门氏菌。沙门氏菌是一种革兰氏阴性菌,是食物中毒最常见的原因。食物中的少量细菌就会导致疾病。它能在8-45℃的温度下,在酸碱度为4-9的食物中生长。动物食品,如生的或未煮熟的肉或尸体、鸭、生鸡蛋,含有生鸡蛋的产品,生的或未消毒的牛奶和乳制品,如黄油、冰淇淋、奶酪,以及一些蔬菜,都可以将这种疾病从动物传播给人类。在农业或清洗新鲜食物中使用受污染的脏水可能也会造成污染。沙门氏菌是泰国食物中毒的第二大原因,仅次于金黄色葡萄球菌,患病率约为5.08%。此外,沙门氏菌也是鸡肉出口行业的一个重要问题。泰国冷冻猪肉出口曾多次被叫停。由于在冷冻鸡肉和猪肉中发现沙门氏菌污染,肉类产品被拒之门外,给出口商造成了损失。如果用含有适量生物发酵鱼腥草的食物混合物饲养鸡和猪,以便用饲养鸡和猪的标准方法建立对沙门氏菌的免疫力,则可以减少农场中抗生素的使用量。在农场中使用的为防止动物感染的抗生素,即使在最小有效剂量内,仍会有一些残留。可以用生物发酵的鱼腥草来代替抗生素的使用。生物发酵的鱼腥草粉末将促进鸡和猪的免疫力。随着用量的减少,宰杀好的肉中没有有毒残留物。本实验的小鼠免疫试验表明,小鼠白细胞能杀死99.82%的B群沙门氏菌。
5、A组链球菌。这种病原体会引起喉咙发炎或链球菌性咽喉炎,扁桃体炎,也可能影响喉部。链球菌性咽喉炎是儿科患者咽喉痛的常见原因(37%),如果没有足够的治疗,可能会导致风湿热。风湿热是许多器官系统的炎症,包括心脏病、多关节炎、风湿性舞蹈病、皮下结节和皮肤(边缘红斑)。A组链球菌是泰国一种重要的坏死性或食肉性细菌。据报道,儿童和成人中每10万人中约有15.5例食肉细菌感染,死亡率约为17-49%。从我们在实验室进行的小鼠免疫试验来看,小鼠的白细胞可以杀死99.83%的A组链球菌。
为了研究乳酸杆菌属DNA和死细胞的有效性,使用从鱼腥草生物发酵汁提取物中提取出的植物乳杆菌和干酪乳杆菌的DNA,在100摄氏度中加热30分钟将乳酸杆菌属灭活。给四只小鼠皮下注射250毫克的DNA。10天后通过联酶免疫测定法(ELISA) 检测白血球介素-2(IL-2)、白细胞介素-12(IL-12)和IF-γ的抗体。结果显示,干酪乳杆菌和植物乳杆菌死亡细胞的免疫刺激迅速,且可以激发针对病原体的抗体。
干酪乳杆菌的DNA片段能促进白细胞破坏各种致病菌,刺激小鼠产生肿瘤坏死因子-α(TNF-α)。干酪乳杆菌(DNA片段)可在10天内激发小鼠的免疫系统(如IgM、IgG 1、IgG2a、IgG2b)。(抗体滴度:12800-204800)
免疫系统受到激发的小鼠的血清有杀菌作用,可杀死表1中的5种病原体。
表1
通过用沸水煮30分钟,或使用称为多核苷酸的RNA片段的方法可以将干酪乳杆菌和植物乳杆菌从生物发酵的鱼腥草中分离出来,虽然是死细胞的形式,也可以调节上述小鼠的免疫系统。
β-葡聚糖是存在于微生物酵母细胞壁结构中的一种成分。称为酿酒酵母的微生物酵母含有30-35%的β-葡聚糖,是一种复杂的糖分子。根据上述方法,本生物发酵方法的实施例可以将β-葡聚糖含量提高到比新鲜的鱼腥草叶中的含量高9倍。β-葡聚糖可以刺激骨髓产生干细胞并将其持续释放到血液中,其机制是β-葡聚糖结合到巨噬细胞的受体dectin-1上,并促进巨噬细胞产生MMP-9(基质金属蛋白酶-9)酶,该酶能够降解将干细胞附着到骨髓上的SDF-1/CXCR4轴蛋白。这样,更多干细胞将从骨髓释放到血液中。
许多医学科学研究和发展论文报道说,干细胞是全身真正的修复和再生单位。干细胞是身体的储备细胞,负责修复受损的细胞、组织或器官,修复各种类型组织的功能障碍,使其在任何时候天都能正常工作。因此,如果血液中有足够的干细胞,身体就能够保持平衡工作,而不会发生任何退行性疾病。干细胞医学表明,阿尔茨海默病和所有类型的退行性疾病都是由血液中干细胞数量减少引起的。当使用来自酿酒酵母的天然物质作为药物配方的混合物时,酵母细胞壁的主要成分β-葡聚糖可以支持身体的骨髓将干细胞释放到血液中。从而能够减缓身体的退化或能使身体恢复正常功能,特别是在身体有足够营养的情况下。根据本发明,生物发酵的鱼腥草提取物结合主流医学原理可以治疗大约70种退行性疾病。
本发明人已经研发生物发酵鱼腥草的方法超过20年,并且记录了现场数据,例如:
1、生物发酵的鱼腥草提取物的使用,
a.液体形式,5-20毫升,每日2次,持续使用一个月,或者
b.粉末形式,200-400毫克,每日两次,持续使用一个月
患者遍布泰国和邻近国家。从现场记录来看,痊愈或好转的病例数有:
-心血管疾病158例
-糖尿病141例
-骨质疏松症和骨关节炎102例
-疲劳性眩晕68例
-自身免疫性疾病64例
-呼吸系统疾病60例
-老年性痴呆、皱纹或硬皮症58例
-高脂血症与脂肪阻塞血管54例
-胃溃疡和GERD 52例
-头痛和偏头痛性疾病45例
-神经突出42例
-糖尿病引起的视力模糊37例
-各种器官肿瘤35例
-慢性肾脏病22例
-痛风14例
-健忘症10例
-病毒感染性疾病9例
-前列腺肥大7例
-上呼吸道感染伴慢性炎症6例
-地中海贫血6例
-肠易激综合征5例
-对1500例疑难杂症有效
2、本发明人捐赠了1万粒生物发酵鱼腥草粉胶囊,每粒胶囊含有220毫克鱼腥草粉末,于2014年8月3日通过塞拉利昂大学校长向塞拉利昂的埃博拉病毒感染患者提供。其中一名在塞拉利昂工作的泰国人担任协调员,同时也是一名在塞拉利昂首都弗里敦中心医院工作的医生,他收到了一些鱼腥草胶囊,用于埃博拉患者的治疗。一些鱼腥草胶囊被分发给感染埃博拉病毒的村民,一些胶囊被送往联合国,与来自其他20个国家的捐赠药物一起在几内亚的临时药物检测中心接受检测。结果显示,住在上述泰国协调员附近村庄的埃博拉患者服用含有220毫克的鱼腥草胶囊后,呈现有益效果。被感染的村民仅在3天内就痊愈了。正如塞拉利昂首都弗里敦中心医院的医生用鱼腥草胶囊治疗的埃博拉感染患者,以及几内亚联合国测试中心的测试,结果也显示生物发酵鱼腥草对埃博拉这种严重的病毒性出血性感染同样有效。
根据上述第1项和第2项现场记录数据,本发明人对本实施例的生物发酵鱼腥草的特性很有信心。其可以更好地增强免疫系统、消除病原体以及恢复、修复和激发身体的细胞活性。根据本发明人和试验小组在老鼠身上的实验和使用生物发酵鱼腥草治疗上述埃博拉病毒感染,以及各种疾病如严重型出血发热的经验,病人的情况均有所好转。根据本实施例,生物发酵的鱼腥草的特性可以触发骨髓释放干细胞,其量达到应对炎症的程度。当在血流中循环的某些干细胞迁移到受损组织或炎性细胞时,它将渗出毛细血管并移动到细胞或受损组织,然后分化为靶细胞或组织,以恢复该细胞或分化为自然杀伤细胞或身体清除病毒或修复受损细胞所需的其他细胞。如果疾病的症状比炎症更严重,那么干细胞可以更好地检测并加速让更多的干细胞从骨髓中释放出来。此外,实验发现,根据本实施例提取的生物发酵鱼腥草具有减少身体中有炎症的细胞因子和酶的能力,例如肿瘤坏死因子-α(TNF-α)和白細胞介素-1β(IL-1β)、白血球介素-6(IL6)和诱导型一氧化氮合酶(iNOS)。
本发明中的生物发酵鱼腥草提取物中含有的大量槲皮素具有抗氧化特性,并且还能引起超氧化物歧化酶的活性,所述超氧化物歧化酶是身体最强的抗氧化剂。槲皮素和超氧化物歧化酶有助于加强抗氧化功能,减轻彼此的炎症。它可以减少生病期间轻微和严重的炎症组织。炎症较少的区域将被掩盖,而炎症较多的区域将被干细胞检测到,这样更多干细胞就会迁移到炎症区域。通过这一过程,身体将能够以最大效率利用从骨髓中释放的干细胞。这就是本发明的发酵鱼腥草中的β-葡聚糖产生的反应。
本发明中的生物发酵鱼腥草粉末的浓缩提取物,当用因链脲佐菌素和高脂肪饲料而诱发糖尿病的大鼠进行测试时,显示出生物发酵的鱼腥草粉末逐周使血清胰岛素激素增加、血糖水平降低,并且还增加了葡萄糖耐受性水平。实验中的所有小鼠都显示出糖尿病症状的显著减轻。图1显示,小鼠可以通过减少水和食物的摄入量来维持体重。
图1-8中的HFD、HFD-STZ和HC缩写代表多脂饮食,图1-8的HFD-STZ缩写代表含有链脲佐菌素的多脂饮食,图1-8中的HC代表生物发酵的鱼腥草提取物。食用生物发酵鱼腥草粉末的小鼠可以使用糖作为细胞的能量来源,并且胰腺的胰岛β细胞数量增加了,如图2所示。
空腹血糖(FBG)的检查结果显示,在相同剂量下,比使用标准糖尿病药物二甲双胍的效果更好,如图3所示。
生物发酵的鱼腥草通过减少炎症和胰腺中与炎症过程相关的酶,如肿瘤坏死因子-α (TNF-α)、白血球介素-6(IL6)、I白細胞介素1β(L-1β)、环氧化酶-2(COX-2)和诱导型一氧化氮合酶(iNOS),对胰腺起到抗炎作用,如图(4)、(5)、(6)、(7)和(8)所示。
此外,生物发酵鱼腥草粉还能增加顽固性脂肪细胞对胰岛素激素的敏感性。因此,根据本实施例,生物发酵的鱼腥草粉末也具有抗糖尿病的特性。
总之,根据该实施例,生物发酵的鱼腥草粉末可以为人类和动物提供更有用的活性药物成分。如图9所示,该实施例可以产生高达9倍的β-葡聚糖,每千克鱼腥草可产生高达31,798毫克的槲皮素,而如图10所示,天然鱼腥草仅含有12.67毫克的槲皮素,即对于相同量的鱼腥草,使用该实施例处理过后比天然来源产生了高达2,509倍的槲皮素。所以,该实施例适用于将来将鱼腥草植物配方加工成草药、食品补充剂和化妆品的目的。
检测报告
分析结果
注:
批准人:(签字)
Orapan Jantarangsri
代表实验室服务处清迈办公室主管签字
检测报告
分析结果
批准人:(签字)
(Somsak Tharatha)
实验室服务处清迈办公室主管
图10
发明内容
进行强化的草药生物发酵过程是为了获得更多能够用于激发人类、动物和植物的身体免疫系统的活性药物成分。该发酵过程如下:称取完好的新鲜鱼腥草叶,彻底冲洗,让其沥干,然后放入发酵罐中来完成。称取甘蔗粉,放入另一个罐中,用清水溶解,然后将甘蔗混合物倒入所述发酵罐中。将发酵罐盖子盖紧,放在阳光下暴晒1-12个月。从发酵罐中取出鱼腥草叶,在100℃的热空气烘箱中干燥8-12小时,直至完全干燥。最后把干叶磨成细粉。
将粉末与发酵罐中的发酵水以1∶2的重量比混合,在烘焙罐中充分搅拌。打开烘焙罐电机,点燃煤气灶,使烘焙罐外部温度上升到100-150℃。烘焙罐需缓慢旋转1小时,在此期间,靠近烘焙罐内侧的湿鱼腥草粉末的温度将在短时间内达到150℃左右。之后,在100℃的热空气烘箱中干燥鱼腥草粉末8-12小时,以获得更浓缩的鱼腥草提取物。
重复上述步骤,将浓缩的鱼腥草粉末与发酵罐中剩余的发酵水以1:2的重量比混合,直到用完所有的发酵水。最终浓缩的鱼腥草粉末将含有更多的槲皮素,也可以用作更好的草药配方的成分。
这种发酵草药提取物加工方法的目的是为了生产一种浓缩的生物发酵鱼腥草粉末,其具有更高浓度的植物化学物质,特别是槲皮素和β葡聚糖,它们的含量相比天然草药中的含量增加更多,以便更好地用于治疗人类和动物的各种退化性疾病和传染性疾病。还可以用于减少或替代抗生素的使用,也可以用作辅助药物。
实施方式
根据本发明,100重量百分比的鱼腥草的浓缩草药提取物是由发酵剂组成,所述发酵剂是由与如下成分混合的酿酒酵母、干酪乳杆菌(GenBank基因数据库序号:AF320255.1)和植物乳杆菌(GenBank基因数据库序号:AF320256.1)以及:
-完整、无缺陷且干净的鱼腥草叶,5-20重量百分比
-干净的水,15-70重量百分比
-甘蔗粉,4-10重量百分比
制备发酵提取物的最佳成分比例是由与下列成分按比例混合的发酵剂、酿酒酵母、干酪乳杆菌(GenBank基因数据库序号:AF320255.1)和植物乳杆菌(GenBank基因数据库序号:AF320256.1)以及:
-完整、无缺陷且干净的鱼腥草叶,20重量百分比
-干净的水,70重量百分比
-甘蔗粉,10重量百分比
生产过程的步骤如下:
1、称取完整、无缺陷和干净的鱼腥草叶,放入1000升白色塑料食品级发酵罐中。
2、称取70公斤甘蔗粉,放入另一个罐中,加入清水,充分搅拌,直到所有甘蔗粉溶解,得到7%的糖溶液。再加入发酵剂、酿酒酵母、干酪乳杆菌(GenBank基因库序号:AF320255.1)和植物乳杆菌(GenBank基因库序号:AF320256.1)。
3、将第2步中的混合物放入第1步中的发酵罐中,直到几乎填满发酵罐。将发酵罐紧闭,在封闭空气条件下放置1个月,在发酵罐上设置一个小排气孔。
4、仍然紧闭发酵罐的盖子,并置在40度的温度中或暴露在阳光下3-12个月。
5、从发酵槽中取出鱼腥草叶,在100℃的热空气烘箱中干燥,并研磨成细粉。
6、将步骤5中的细粉与发酵罐中的发酵水以1:2的重量比在烘焙罐中混合。点燃煤气灶,同时打开烘焙罐电机,使烘焙罐内部温度上升到100-150℃。在1小时的烘烤过程中,湿的鱼腥草将短暂接触100-150℃的温度数次。
7、在100℃的热风烘箱中干燥鱼腥草粉末8-12小时。
8、以2:1的重量比将剩余的发酵水放入步骤7的干燥粉末中,并在烘焙罐中重复相同的过程1小时(如步骤6)。
9、按照步骤7,在100℃的热空气烘箱中干燥粉末8-12小时。
10、重复步骤8和9,直到剩余的发酵水全部用完。这样我们就可以得到所需的浓缩鱼腥草粉末。
11、最终的鱼腥草粉末可用作草药和食品补充剂的高浓度活性药物成分使用。
最佳实施方式
如本发明的全部公布的主题中所述。
Claims (5)
1.一种刺激身体免疫系统的草药配方,其特征在于,草药粉末的制备过程包括发酵剂,所述发酵剂包括酿酒酵母、干酪乳杆菌(GenBank基因数据库序号:AF320255.1)和植物乳杆菌(GenBank基因数据库序号:AF320256.1),以及:
-无缺陷的鱼腥草叶,5-20重量百分比;
-甘蔗粉,4-10重量百分比;
-干净的水,15-70重量百分比。
2.根据权利要求1所述的一种刺激身体免疫系统的草药配方,其特征在于,所述草药粉末的制备成分包括:
-无缺陷的鱼腥草叶,20重量百分比;
-甘蔗粉,10重量百分比;
-干净的水,70重量百分比。
3.根据权利要求1-2所述的一种刺激身体免疫系统的草药配方的制备工艺,其特征在于,所述制备工艺包括以下步骤:
a.取一定重量的无缺陷的鱼腥草叶,彻底洗净,沥干水分。放入白色塑料食品级发酵罐中;
b.称取甘蔗粉,放入另一个罐中,然后加入发酵剂,即酿酒酵母、干酪乳杆菌(GenBank基因数据库序号:GenBank:AF320255.1)和植物乳杆菌(GenBank基因数据库序号:AF320256.1),再加入清水至1000升;
c.将b步骤中获得的混合物从第二个罐倒入第一个罐,覆盖住鱼腥草叶;关闭罐盖,要留有足够的进气口,防止发酵罐内压力过高。静置1个月,直到不再有气泡冒出。然后把所述罐盖盖紧,放在室外可以晒到阳光的地方3-12个月;
d.在100℃的热风烘箱中干燥鱼腥草发酵叶8-12小时,然后研磨成粉末;
e.将所述粉末与发酵水以1:2的重量比混合,然后在烘焙罐中混合。点燃煤气炉,同时打开烘焙罐电机,转动所述烘焙罐,使所述烘焙罐内表面温度达到100-150℃,在1小时的烘烤过程中,湿的鱼腥草将短暂达到100-150℃的温度数次;
f.在100℃的热风烘箱中干燥所述鱼腥草粉末8-12小时;
g.重复步骤e和步骤f,将剩余的发酵水与所述干燥粉末以重量比2∶1的比例混合,并在所述烘焙罐中重复1小时,直到罐中的发酵水用完。然后我们就可以得到所需的鱼腥草粉末;
h.最终的鱼腥草粉末可用作草药和食品补充剂的高浓度活性药物成分使用。
4.根据权利要求3所述的实施方案,是将所述鱼腥草粉末作为药物或膳食补充剂的混合物,其特征在于,每千克体重每天摄入10至100毫克,可用于预防和治疗由病原体如类鼻疽伯克霍尔德氏菌、福氏志贺氏菌、金黄色葡萄球菌、沙门氏菌痢疾、A组链球菌引起的感染,并用于预防和治疗由鼻病毒和其他病毒造成的感染,如流感、基孔肯雅热、麻疹、水痘、天花、腮腺炎、单纯疱疹、带状疱疹、甲型肝炎、乙型肝炎、丙型肝炎、登革热、艾滋病毒、伊波拉病毒、新型冠状病毒引起的感染。
5.根据权利要求3所述的实施方案,是将所述鱼腥草粉末作为药物或膳食补充剂的混合物,其特征在于,每千克体重每天摄入10至100毫克,可用于预防和治疗退行性疾病,如1型和2型糖尿病,另外还包括预防和治疗由糖尿病引起的视力模糊、心血管疾病、骨质疏松和骨关节炎、慢性头晕和疲劳、消化性溃疡、胃食管反流病(GERD)、地中海贫血、头痛和偏头痛、椎间盘突出症、肺癌、乳腺癌、白血病、慢性肾病、痛风、前列腺增生、更年期综合征、帕金森病、类风湿性关节炎、精神分裂症偏执和阿尔茨海默症等。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TH2001002715 | 2020-05-18 | ||
TH2001002715 | 2020-05-18 | ||
PCT/TH2020/000057 WO2021236023A1 (en) | 2020-05-18 | 2020-08-11 | Fermented - concentrated extraction method of houttuynia cordata for medical using |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115697365A true CN115697365A (zh) | 2023-02-03 |
Family
ID=78708746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080101111.5A Pending CN115697365A (zh) | 2020-05-18 | 2020-08-11 | 药用鱼腥草的发酵浓缩提取方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115697365A (zh) |
WO (1) | WO2021236023A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114403314A (zh) * | 2022-01-21 | 2022-04-29 | 湖州市千盛泉中草药种植有限公司 | 一种鱼腥草柠檬饮料及其制备方法 |
CN114403423B (zh) * | 2022-02-18 | 2023-12-12 | 四川川娃子食品有限公司 | 一种折耳根烧椒酱及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106070896A (zh) * | 2016-07-05 | 2016-11-09 | 南方医科大学 | 鱼腥草发酵茶及其制备方法 |
CN107712878A (zh) * | 2017-11-08 | 2018-02-23 | 陈永恒 | 一种鱼腥草酵素及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100568689B1 (ko) * | 2005-03-10 | 2006-04-07 | 김강민 | 어성초를 이용한 기능성 발효사료와 그 제조방법과 그것을이용한 돼지의 사육방법 및 그로부터 얻어진 돈육(豚肉) |
KR100755643B1 (ko) * | 2006-06-14 | 2007-09-04 | 이승아 | 어성초 추출발효액의 제조방법 |
KR20120133133A (ko) * | 2011-05-30 | 2012-12-10 | 한국 한의학 연구원 | 생약 추출물 또는 이의 유산균 발효물을 포함하는 호흡기 질환의 예방 또는 치료용 조성물 |
-
2020
- 2020-08-11 WO PCT/TH2020/000057 patent/WO2021236023A1/en active Application Filing
- 2020-08-11 CN CN202080101111.5A patent/CN115697365A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106070896A (zh) * | 2016-07-05 | 2016-11-09 | 南方医科大学 | 鱼腥草发酵茶及其制备方法 |
CN107712878A (zh) * | 2017-11-08 | 2018-02-23 | 陈永恒 | 一种鱼腥草酵素及其制备方法 |
Non-Patent Citations (1)
Title |
---|
KHANUTSANAN WORANAM等: "Anti-inflammatory activity of the dietary supplement Houttuynia cordata fermentation product in RAW264.7 cells and Wistar rats", PLOS ONE, vol. 15, no. 3, pages 1 - 18 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021236023A1 (en) | 2021-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103655637B (zh) | 胚芽乳酸杆菌cmu995菌株的制药用途 | |
JP2012161334A (ja) | 発酵及び培養方法、植物発酵エキス並びに植物発酵エキス配合物 | |
CN115697365A (zh) | 药用鱼腥草的发酵浓缩提取方法 | |
CN106413724A (zh) | 与多糖聚合物粘合剂缀合的鼠李糖乳杆菌rht‑3201,及其用于预防或治疗特应性疾病的用途 | |
Hou et al. | Beneficial effects of mung bean seed coat on the prevention of high-fat diet-induced obesity and the modulation of gut microbiota in mice | |
CN105533671A (zh) | 一种富硒猴头菇片的制备方法 | |
Kolaylı et al. | Evaluation of anti-Helicobacter pylori activity and urease inhibition by some Turkish authentic honeys | |
JP6742981B2 (ja) | 免疫調節剤及びその用途 | |
CN113519624A (zh) | 一种提高航天员免疫力和抗病毒能力的营养配方及制备方法 | |
RU2233320C2 (ru) | Способ получения биологически активного препарата, биологически активная добавка (бад) к пище пребиотического действия, приводящая к коррекции (нивелированию) метаболического синдрома и лекарственный препарат для регуляции микробиоценоза желудочно-кишечного тракта | |
Peek et al. | In vivo screening of five phytochemicals/extracts and a fungal immunomodulatory protein against colibacillosis in broilers | |
CN112190644A (zh) | 植物发酵物及其制备方法与用于胃脏保健的用途 | |
CN103262940B (zh) | 一种黄粉虫复合蛋白制品及制备方法 | |
KR102443539B1 (ko) | 항암면역 활성을 가지는 흑삼 발효물 및 제조방법 | |
CN104208683B (zh) | 一种抗鸭病毒性疾病的药物组合物、冻干粉、制备方法及应用 | |
US20030161841A1 (en) | Preventive and therapeutic agents for microbe-related syndromes including HIV | |
CN105558350A (zh) | 一种含有中草药复合粗多糖的饲料及其制备方法 | |
CN111317815A (zh) | 复方异麦多维颗粒及其制备方法 | |
CN110522762A (zh) | 一种具有预防和治疗炎症的生物多糖及其应用 | |
CN102641396A (zh) | 一种肠胃疾病用药的制备方法 | |
CN102641497A (zh) | 一种肠胃疾病用药组合物 | |
EP1331006A1 (en) | Dietary supplements comprising growth media | |
Reda et al. | Extraction of Beta-Glucan from Sacchromyces boulardii, Study of its Chemical and Functional Properties, and Comparison of its Immunological Properties with Yeast Extracted from it | |
SK288782B6 (sk) | Probiotický prípravok, spôsob jeho prípravy a použitie probiotického prípravku | |
CN117730958A (zh) | 一种护肝解酒的植物乳杆菌发酵饮品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20230203 |
|
WD01 | Invention patent application deemed withdrawn after publication |